FM19G11-Loaded Gold Nanoparticles Enhance the Proliferation and Self-Renewal of Ependymal Stem Progenitor Cells Derived from ALS Mice.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
23 03 2019
Historique:
received: 21 02 2019
revised: 18 03 2019
accepted: 20 03 2019
entrez: 27 3 2019
pubmed: 27 3 2019
medline: 27 3 2019
Statut: epublish

Résumé

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons. In ALS mice, neurodegeneration is associated with the proliferative restorative attempts of ependymal stem progenitor cells (epSPCs) that normally lie in a quiescent in the spinal cord. Thus, modulation of the proliferation of epSPCs may represent a potential strategy to counteract neurodegeneration. Recent studies demonstrated that FM19G11, a hypoxia-inducible factor modulator, induces epSPC self-renewal and proliferation. The aim of the study was to investigate whether FM19G11-loaded gold nanoparticles (NPs) can affect self-renewal and proliferation processes in epSPCs isolated from G93A-SOD1 mice at disease onset. We discovered elevated levels of SOX2, OCT4, AKT1, and AKT3, key genes associated with pluripotency, self-renewal, and proliferation, in G93A-SOD1 epSPCs at the transcriptional and protein levels after treatment with FM19G11-loaded NPs. We also observed an increase in the levels of the mitochondrial uncoupling protein (

Identifiants

pubmed: 30909571
pii: cells8030279
doi: 10.3390/cells8030279
pmc: PMC6468696
pii:
doi:

Substances chimiques

Benzamides 0
Biomarkers 0
FM19G11 0
MicroRNAs 0
Octamer Transcription Factor-3 0
Pou5f1 protein, mouse 0
SOXB1 Transcription Factors 0
Uncoupling Protein 2 0
Gold 7440-57-5
Superoxide Dismutase-1 EC 1.15.1.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
PTEN Phosphohydrolase EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Acta Neuropathol. 2000 Sep;100(3):275-84
pubmed: 10965797
Br Med Bull. 2010;93:145-59
pubmed: 20015852
Circ Res. 2009 Jul 17;105(2):114-27
pubmed: 19608989
Nature. 1993 Mar 4;362(6415):59-62
pubmed: 8446170
Mol Neurobiol. 2014 Feb;49(1):136-48
pubmed: 23873136
Cell Cycle. 2010 Jul 15;9(14):2803-13
pubmed: 20676050
Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Jun;6(2):111-4
pubmed: 16036435
Exp Neurol. 2011 Sep;231(1):30-7
pubmed: 21620832
Biomater Sci. 2018 Dec 18;7(1):113-124
pubmed: 30444251
Trends Neurosci. 2008 Jun;31(6):279-86
pubmed: 18471905
J Neurol Sci. 2003 Nov 15;215(1-2):57-62
pubmed: 14568129
Nanomedicine (Lond). 2008 Aug;3(4):507-19
pubmed: 18694313
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3155-60
pubmed: 8610185
Nat Rev Neurosci. 2005 Nov;6(11):829-40
pubmed: 16224498
Nat Biotechnol. 2011 Aug 10;29(9):824-8
pubmed: 21832997
AJNR Am J Neuroradiol. 2005 Oct;26(9):2290-300
pubmed: 16219835
Stem Cells. 2012 Oct;30(10):2221-33
pubmed: 22865656
Proc Natl Acad Sci U S A. 2007 May 8;104(19):7933-8
pubmed: 17470778
Trends Mol Med. 2016 Jan;22(1):53-67
pubmed: 26691296
Diabetes. 2007 Feb;56(2):414-23
pubmed: 17259386
J Biol Chem. 2010 Jan 8;285(2):1333-42
pubmed: 19897487
Nat Mater. 2008 Jul;7(7):588-95
pubmed: 18500347
Nat Rev Neurol. 2011 Oct 11;7(11):603-15
pubmed: 21989245
Brain. 2011 Feb;134(Pt 2):506-17
pubmed: 21228060
Exp Neurol. 2014 Mar;253:91-101
pubmed: 24365539
Stem Cells Dev. 2007 Aug;16(4):579-88
pubmed: 17784831
Nat Rev Neurosci. 2001 Nov;2(11):806-19
pubmed: 11715057
Nat Protoc. 2009;4(10):1464-70
pubmed: 19798081
J Neurochem. 2007 Aug;102(4):1125-38
pubmed: 17472707
Exp Neurol. 2017 Jul;293:43-52
pubmed: 28351750
Neurosurgery. 2007 Apr;60(4):601-11; discussion 611-2
pubmed: 17415196
Brain Res Mol Brain Res. 2003 Mar 17;111(1-2):155-64
pubmed: 12654515
J Pharm Sci. 2015 Apr;104(4):1213-29
pubmed: 25559087
Neuropharmacology. 2017 Sep 1;123:175-185
pubmed: 28601397
Drug Discov Today. 2007 Feb;12(3-4):112-24
pubmed: 17275731
Nanomedicine. 2015 Apr;11(3):751-67
pubmed: 25645958

Auteurs

Stefania Marcuzzo (S)

Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. stefania.marcuzzo@istituto-besta.it.

Davide Isaia (D)

Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Development and Stem Cells, CNRS UMR7104, INSERM U964, Université de Strasbourg, 67404 Illkirch CU Strasbourg, France. isaiad@igbmc.fr.

Silvia Bonanno (S)

Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. silvia.bonanno@istituto-besta.it.

Claudia Malacarne (C)

Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. malacarne.c17@gmail.com.

Paola Cavalcante (P)

Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. paola.cavalcante@istituto-besta.it.

Antonella Zacheo (A)

Laboratory for Translational Nanotechnology, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. zacheo@yahoo.com.

Valentino Laquintana (V)

Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70124 Bari, Italy. valentino.laquintana@uniba.it.

Nunzio Denora (N)

Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70124 Bari, Italy. nunzio.denora@uniba.it.

Barbara Sanavio (B)

Laboratory for Nanomedicine, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. barbara.sanavio@gmail.com.

Elisa Salvati (E)

IFOM, the FIRC Institute for Molecular Oncology Foundation, IFOM-IEO Campus, 20139 Milan, Italy. eli.salvati@gmail.com.

Patrizia Andreozzi (P)

IFOM, the FIRC Institute for Molecular Oncology Foundation, IFOM-IEO Campus, 20139 Milan, Italy. pandreozzi@cicbiomagune.es.
CIC biomaGUNE, 20014 San Sebastian, Spain. pandreozzi@cicbiomagune.es.

Francesco Stellacci (F)

Institute of Materials, Ecole Polytechnique Fédérale de Lausanne (EPFL), STI IMX SUNMIL, MXG 030 (Bâtiment MXG), CH-1015 Lausanne, Switzerland. francesco.stellacci@epfl.ch.

Silke Krol (S)

Laboratory for Translational Nanotechnology, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. silke.krol@aol.com.
Laboratory for Nanomedicine, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. silke.krol@aol.com.
IFOM, the FIRC Institute for Molecular Oncology Foundation, IFOM-IEO Campus, 20139 Milan, Italy. silke.krol@aol.com.
IRCCS Azienda Ospedaliera Specializzata in Gastroenterologia "Saverio de Bellis", 70013 Castellana Grotte, Italy. silke.krol@aol.com.

Maravillas Mellado-López (M)

Neuronal and Tissue Regeneration Laboratory, Prince Felipe Research Institute (CIPF), 46512 Valencia, Spain. mmellado@cipf.es.

Renato Mantegazza (R)

Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. renato.mantegazza@istituto-besta.it.

Victoria Moreno-Manzano (V)

Neuronal and Tissue Regeneration Laboratory, Prince Felipe Research Institute (CIPF), 46512 Valencia, Spain. vmorenom@cipf.es.

Pia Bernasconi (P)

Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", 20133 Milan, Italy. pia.bernasconi@istituto-besta.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH